Status:
UNKNOWN
Tuberculosis Drug Levels and Continuous Glucose Monitoring in Diabetic Patients
Lead Sponsor:
London North West Healthcare NHS Trust
Conditions:
Tuberculosis
Diabetes Mellitus
Eligibility:
All Genders
18+ years
Brief Summary
Diabetes significantly increases the risk of developing active tuberculosis (TB). Diabetic patients who do develop TB have worse treatment outcomes and overall mortality. TB also worsens blood glucose...
Detailed Description
This study has been designed as a case control trial analysed via population pharmacokinetic modelling, with the hypothesis that overall exposure to TB medications will be lower in the diabetic than t...
Eligibility Criteria
Inclusion
- Cases:
- Subject aged 18 years of age or over
- Written, informed consent obtained.
- New diagnosis of tuberculosis and starting on anti-tuberculosis treatment
- Known diagnosis of diabetes or a raised IFCC HbA1c level (\>= 48 mmol/mol) at the time of TB diagnosis
- Controls:
- Subject aged 18 years of age or over
- Written, informed consent obtained.
- New diagnosis of tuberculosis and starting on anti-tuberculosis treatment
- IFCC HbA1c level \< 48mmol/mol and no known diagnosis of diabetes
Exclusion
- Subject aged under 18 years
- Inability to give informed consent
Key Trial Info
Start Date :
February 1 2022
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
May 1 2024
Estimated Enrollment :
48 Patients enrolled
Trial Details
Trial ID
NCT05329415
Start Date
February 1 2022
End Date
May 1 2024
Last Update
June 7 2023
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
London North West University NHS University Trust
London, United Kingdom, HA1 3UJ